Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute : Five-year follow-up reportSORENSEN, J. M; VENA, D. A; FALLAVOLLITA, A et al.Journal of clinical oncology. 1997, Vol 15, Num 2, pp 458-465, issn 0732-183XArticle

Shallow junction formation by dopant diffusion from in situ doped polycrystalline silicon chemically vapor deposited in a rapid thermal processorHSIEH, T. Y; CHUN, H. G; KWONG, D. L et al.Applied physics letters. 1990, Vol 56, Num 18, pp 1778-1780, issn 0003-6951Article

Cardiac complications observed in elderly patients following 2'-deoxycoformycin therapyGREM, J. L; KING, S. A; CHUN, H. G et al.American journal of hematology. 1991, Vol 38, Num 3, pp 245-247, issn 0361-8609Article

Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemiaARLIN, Z. A; FELDMAN, E. J; ABRAHAM MITTELMAN et al.Cancer. 1991, Vol 68, Num 6, pp 1198-1199, issn 0008-543XArticle

Chloroquinoxaline sulfonamide : a sulfanilamide antitumor agent entering clinical trialsFISHERMAN, J. S; OSBORN, B. L; CHUN, H. G et al.Investigational new drugs. 1993, Vol 11, Num 1, pp 1-9, issn 0167-6997Article

Short course high dose mitoxantrone with high dose cytarabine is effective therapy for adult lymphoblastic leukemiaARLIN, Z. A; FELDMAN, E. J; DECTER, J et al.Leukemia. 1991, Vol 5, Num 8, pp 712-714, issn 0887-6924Article

Selective deposition of in situ doped polycrystalline silicon by rapid thermal processing chemical vapor depositionHSIEH, T. Y; CHUN, H. G; KWONG, D. L et al.Applied physics letters. 1989, Vol 55, Num 23, pp 2408-2410, issn 0003-6951, 3 p.Article

Differentiating agents in the treatment of human malignanciesCHESON, B. D; JASPERSE, D. M; CHUN, H. G et al.Cancer treatment reviews. 1986, Vol 13, Num 3, pp 129-145, issn 0305-7372Article

Conducting properties of planar irradiated and pristine silicon-fullerite-metal structuresBERDINSKY, A. S; FINK, D; YOO, J. B et al.Applied physics. A, Materials science & processing (Print). 2005, Vol 80, Num 8, pp 1711-1715, issn 0947-8396, 5 p.Article

Phase II clinical trial of didemnin B in patients with recurrent or refractory anaplastic astrocytoma or Glioblastoma multiforme (NSC 325319)MITTELMAN, A; CHUN, H. G; PUCCIO, C et al.Investigational new drugs. 1999, Vol 17, Num 2, pp 179-182, issn 0167-6997Article

Simultaneous measurement of the cell-differentiating agent hexamethylene bisacetamide and its metabolites by gas chromatographyROTH, J. S; KELLEY, J. A; CHUN, H. G et al.Journal of chromatography. Biomedical applications. 1994, Vol 652, Num 2, pp 149-159, issn 0378-4347Article

Patient treatment on a compassionate basis : documentation of high adverse drug reaction rateLEYLAND-JONES, B; DAVIES, B. R; HOTH, D. F et al.Annals of oncology. 1992, Vol 3, Num 1, pp 59-62, issn 0923-7534Article

A phase I trial of high-dose diaziquone and autologous bone marrow transplantation : an Illinois cancer council studySTIFF, P. J; SCOTT MCKENZIE, R; JOHNSON, C et al.Journal of clinical oncology. 1991, Vol 9, Num 8, pp 1487-1494, issn 0732-183XArticle

Fludarabine phosphate in refractory hairy cell leukemiaKRAUT, E. H; CHUN, H. G.American journal of hematology. 1991, Vol 37, Num 1, pp 59-60, issn 0361-8609Article

Central nervous system toxicity of fludarabine phosphateCHUN, H. G; LEYLAND-JONES, B. R; CARYK, S. M et al.Cancer treatment reports. 1986, Vol 70, Num 10, pp 1225-1228, issn 0361-5960Article

Hexamethylene bisacetamide: a polar-planar compound entering clinical trials as a differentiating agentCHUN, H. G; LEYLAND-JONES, B; WITTES, R. E et al.Cancer treatment reports. 1986, Vol 70, Num 8, pp 991-996, issn 0361-5960Article

Power correlation for EGSTAR agitatorOHISHI, T; HIRAOKA, S; KATO, Y et al.Kagaku kōgaku ronbunshū. 1998, Vol 24, Num 6, pp 907-911, issn 0386-216XArticle